...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Circulation journal >Vasodilatory effect of subsequent administration of fasudil, a rho-kinase inhibitor, surpasses that of nitroglycerin at the concentric coronary stenosis in patients with stable angina pectoris.
【24h】

Vasodilatory effect of subsequent administration of fasudil, a rho-kinase inhibitor, surpasses that of nitroglycerin at the concentric coronary stenosis in patients with stable angina pectoris.

机译：稳定型心绞痛患者在同心性冠状动脉狭窄中，随后使用rho激酶抑制剂法舒地尔的血管舒张作用优于硝酸甘油。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Recent studies have suggested that the Rho/Rho-kinase mediated pathway (Rho-kinase pathway) regulates the vasomotion of arteries in pathological conditions. However, it remains unclear regarding whether this pathway regulates the coronary vasomotion of atherosclerotic lesions. METHODS AND RESULTS: The coronary diameter at the concentric stenotic site, which is considered to reflect the whole circumferential atherosclerosis, in patients with stable angina pectoris (SAP; n=11) and the control site in patients with SAP and chest pain syndrome (CPS; n=9), was measured at baseline and after the intracoronary administration of nitroglycerin (200 microg) and the subsequent intravenous infusion of fasudil (30 mg for 30 min), a Rho-kinase inhibitor, during coronary angiography. The change in the diameter with fasudil at the concentric stenotic site (22.0+/-10.0%) was significantly higher than that with nitroglycerin (4.7+/-6.0%, p<0.001) in patients with SAP. Meanwhile, the vasodilatory effect of nitroglycerin and fasudil at the control site was similar in both group of patients (25.5+/-17.3% and 21.9+/-14.9% in SAP and 34.4+/-20.8% and 33.2+/-23.6% in CPS, respectively). CONCLUSIONS: The vasodilatory effect of the subsequent administration of fasudil surpassed that of nitroglycerin at the concentric coronary stenosis in patients with SAP, thus suggesting that the Rho-kinase pathway regulates the coronary vasomotion of atherosclerotic lesions.
机译：背景：最近的研究表明，Rho / Rho激酶介导的途径（Rho激酶途径）在病理情况下调节动脉的血管运动。然而，关于该途径是否调节动脉粥样硬化病变的冠状血管运动尚不清楚。方法和结果：稳定型心绞痛（SAP; n = 11）患者和控制部位的同心性狭窄部位的冠状动脉直径被认为反映了整个圆周动脉粥样硬化。 ; n = 9），是在冠状动脉造影期间在基线时以及在冠状动脉内施用硝酸甘油（200微克）并随后静脉内输注Rho激酶抑制剂法舒地尔（30毫克，持续30分钟）后测量的。在SAP患者中，法舒地尔在同心狭窄部位的直径变化（22.0 +/- 10.0％）明显高于硝化甘油的直径变化（4.7 +/- 6.0％，p <0.001）。同时，两组患者在对照组的硝酸甘油和法舒地尔的血管舒张作用相似（SAP组为25.5 +/- 17.3％和21.9 +/- 14.9％，SAP组为34.4 +/- 20.8％和33.2 +/- 23.6％分别在CPS中）。结论：随后给予法舒地尔的血管舒张作用优于硝酸甘油在SAP患者的同心冠状动脉狭窄中的血管舒张作用，因此表明Rho激酶通路可调节动脉粥样硬化病变的冠状动脉血管舒张。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号